Adjuvant radiotherapy after lumpectomy allows a local long-term control of the order 85 to 95% with a survival rate equivalent to that of the totally mastectomy. The diminution of the local recurrence rate after irradiation post- lumpectomy is also associated to a best global survival than only the surgery. The adjuvant radiotherapy after partially or totally mastectomy for the progressive tumors is a therapeutic standard (Early Breast Cancer Trialists' Collaborative Group 2011). The aim of our trial of routine care is to record our practices under this breast adjuvant radiotherapy.
Patients responding criteria for selection and not objecting to participate in this trial will address the quality of life questionnaires at baseline and during their standard follow-up (1, 6, 12 and 24 months after the end of radiotherapy). The data of toxicity and disease-free survival will be collected from data on medical record of the patient. The therapeutic support and monitoring are standard.
Study Type
OBSERVATIONAL
Enrollment
500
Centre Léonard de Vinci
Douai, France
Centre Oscar Lambret
Lille, France
acute and tardive toxicity according to NCI-CTCAE v4.0
according to NCI-CTCAE v4.0
Time frame: up to 5 years
Quality of life according to QLQC-30
Quality of life according to QLQC-30
Time frame: up to 24 months
Quality of life according to BR-23 module
Quality of life according to BR-23 module
Time frame: up to 24 months
Disease free survival
according to RECIST 1.1
Time frame: up to 5 years
esthetic results
by physician and patient according to a scale (good, excellent, moderate and poor)
Time frame: up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.